Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic
steatohepatitis (NASH), represent a growing worldwide epidemic and a high unmet medical …

Nonalcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Its
more advanced subtype, nonalcoholic steatohepatitis (NASH), connotes progressive liver …

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …

INTRODUCTION Proteins are essential functional units of the human body and represent
the largest class of drug targets. RATIONALE Broad-capture proteomics has the potential to …

Metabolic (dysfunction)-associated fatty liver disease (MAFLD) affects up to a third of the
global population; its burden has grown in parallel with rising rates of type 2 diabetes …

Background Studies have reported a significant association between non-alcoholic fatty liver
disease (NAFLD) and increased incidence of cardiovascular disease (CVD). However, the …

Epigenetics regulates gene expression and has been confirmed to play a critical role in a
variety of metabolic diseases, such as diabetes, obesity, non-alcoholic fatty liver disease …

Metabolic associated fatty liver disease (MAFLD) is the principal worldwide cause of liver
disease and affects nearly a quarter of the global population. The objective of this work was …

Non-alcoholic fatty liver DISEASE (NAFLD) is the most common chronic liver disease in
Western countries and affects approximately 25% of the adult population. Since NAFLD is …

This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty
liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and …